Sygnature Discovery

JULY 31, 2023

Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. Previous acquisitions made were Peak Proteins in April 2022 and SB Drug Discovery in January 2023. Marc Lebel, Pharm.

Computational Chemistry 52

Computational Chemistry Science Clinical Trials Pharmaceutical Companies 52

Sygnature Discovery

MARCH 24, 2022

When DMPK scientist Lynette Ongeri joined Sygnature this month, she unknowingly helped us reach a landmark we couldn’t be prouder of… Sygnature Discovery – or Sygnature Chemical Services Ltd, as it was known then – opened its doors in 2004 with five colleagues. Want to join Lynette in working at an innovative integrated drug discovery CRO?

Computational Chemistry 52

Computational Chemistry International Science Pharmaceuticals 52

Drug Target Review

SEPTEMBER 20, 2023

“AI will not replace drug discovery scientists, but drug discovery scientists who use AI will replace those who don’t” – comment during EFMC meeting 2018 Progressing a drug molecule from concept to commercialisation typically takes 10-15 years and has high associated costs of up to $2 billion per launched drug, if all failures are factored in.

Drugs 105

Drugs Metabolic Stability Computational Chemistry Pharmaceuticals 105